IP Library › Granted Patent US 11,479,556

Granted Patent B1

US 11,479,556 · App. 15/734,774 · Granted Oct 25, 2022

Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway

Inventors: Daniel W. Robbins (San Francisco, CA); Arthur T. Sands (San Francisco, CA); Joel McIntosh (San Francisco, CA); Jeffrey Mihalic (San Francisco, CA); Jeffrey Wu (San Francisco, CA); Daisuke Kato (San Francisco, CA); Dahlia Weiss (San Francisco, CA); Ge Peng (San Francisco, CA)

Assignee: NURIX THERAPEUTICS, INC.

C07D487/10 C07D401/14 C07D413/14 C07D417/14 C07D471/10 C07D487/04 C07D491/107 C07D498/10

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 11,479,556
App. No.: 15/734,774
Granted: Oct 25, 2022
Kind: B1

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present invention relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Claims (410)

1. A compound of Formula (A)

or a pharmaceutically acceptable salt thereof, wherein

W is CH or N;

D is a bond or —NH—;

Ring A is phenyl, a 9-10 membered bicyclic aryl, a 5-6 membered partially or fully unsaturated monocyclic heterocycle, or a 9-10 membered bicyclic heteroaryl, wherein the monocyclic heterocycle and bicyclic heteroaryl of ring A each possess 1-3 heteroatoms independently selected from N, O, or S, wherein ring A is optionally and independently substituted with up to 3 substituents selected from halo, —CN, —COOH, NH 2 , and optionally substituted C 1-6 alkyl;

Ring B is a phenyl, a 5-6 membered heteroaryl, a 4-6 membered heterocycloalkyl, or a 8-10 membered spiro bicyclic heterocycle, wherein ring B is optionally substituted, and wherein the heteroaryl and heterocycloalkyl of ring B has 1-3 heteroatoms independently selected from N, O, or S;

L is —X 1 —X 2 —X 3 —X 4 —X 5 —;

X 1 is a bond, —C(O)—N(R)—, —N(R)—C(O)—, —(O—CH 2 —CH 2 ) m —, —O(C 6 H 4 )—, —(O—CH 2 —CH 2 —CH 2 ) m , —C 1-5 alkyl-, 7-12 membered spiro or fused bicyclic heterocycloalkyl having 1-3 heteroatoms independently selected from N, O, or S, or 4-6 membered monocyclic heterocycloalkyl having 1-2 heteroatoms independently selected from N, O, or S, wherein each of the monocyclic and bicyclic heterocycloalkyl of X 1 is optionally substituted with —CH 3 ;

X 2 is a bond, —(O—CH 2 —CH 2 ) n —, —(CH 2 —CH 2 —O) n —, —N(R)—C(O)—, —N(R)—, —C(O)—, —C 1-5 alkyl-, 4-6 membered monocyclic cycloalkyl, or 4-6 membered monocyclic heterocycloalkyl having 1-2 heteroatoms independently selected from N, O, or S;

X 3 is a bond, —C 1-8 alkyl-, —C≡C—, 4-6 membered cycloalkyl, —N(R)—, —N(R)—C(O)—, —(O—CH 2 —CH 2 ) p —, —(CH 2 —CH 2 —O) p —, 4-6 membered heterocycloalkyl having 1-2 heteroatoms independently selected from N, O, or S wherein the heterocycloalkyl is optionally substituted with —CH 3 ;

X 4 is a bond, —CH 2 —CH 2 —N(R)—, —N(R)—, —C 1-4 alkyl-, —(O—CH 2 —CH 2 —CH 2 ) m —, a 5-6 membered saturated, partially unsaturated, or fully unsaturated carbocycle, or a 5-6 membered saturated, partially unsaturated, or fully unsaturated heterocycle having 1-3 heteroatoms independently selected from N, O, or S;

X 5 is a bond, —C 1-4 alkyl-, —N(R)—, —O—, —C(O)—, or —C(O)—N(R)—;

each R is independently —H or —C 1-3 alkyl; and

each of m, n, and p is independently an integer from 1 to 3; and

wherein

each R 2 is independently halo, —CN, or C 1-4 alkyl, wherein each C 1-4 alkyl is optionally and independently substituted with up to three instances of halo, —CN, —COOH, —COONH 2 , —NH 2 , or —CF 3 ;

each R″ and R′″ are independently H or, together with the atoms to which they are attached, form a 5-6 membered partially unsaturated or fully unsaturated benzofuzed heterocycle;

each Z is —C(R A ) 2 — or —C(O)—;

each R A is independently —H or —C 1-4 alkyl; and

q is 0, 1, or 2.

2. The compound or pharmaceutically acceptable salt of claim 1 , wherein ring B is an optionally substituted 5-6 membered heterocycloalkyl having 1-2 nitrogen atoms.

3. The compound or pharmaceutically acceptable salt of claim 1 , wherein ring B is an optionally substituted 5-6 membered heteroaryl having 1-2 heteroatoms independently selected from N and S.

4. The compound or pharmaceutically acceptable salt of claim 1 , wherein ring B is

wherein R 10 is

and wherein R 1 is a C 1-4 alkyl group.

5. The compound or pharmaceutically acceptable salt of claim 1 , wherein ring B is

wherein R 10 is

6. The compound or pharmaceutically acceptable salt of claim 4 , wherein ring B is

7. The compound or pharmaceutically acceptable salt of claim 4 , wherein R 10 is

8. The compound or pharmaceutically acceptable salt of claim 4 , wherein ring A is

or wherein ring A′ together with the phenyl ring to which it is fused form a 9-10 membered bicyclic aryl or a 9-10 membered bicyclic heteroaryl wherein the bicyclic heteroaryl has 1-3 heteroatoms independently selected from N, O, or S.

9. The compound or pharmaceutically acceptable salt of claim 1 , wherein ring A is

10. The compound or pharmaceutically acceptable salt of claim 1 , or a pharmaceutically acceptable salt thereof, wherein at least one of X 1 , X 2 , and X 5 is —N(R)—,

—C(O)—N(R)—, or —CH 2 —.

11. The compound or pharmaceutically acceptable salt of claim 1 , wherein X 1 is —C(O)—N(R)—.

12. The compound or pharmaceutically acceptable salt of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X 2 is —(O—CH 2 —CH 2 ) n —, —(CH 2 —CH 2 —O) n —, or —C 1-5 alkyl-.

13. The compound or pharmaceutically acceptable salt of claim 1 , wherein X 3 is a bond, —C≡C—, —C 1-4 alkyl-, or —N(R)—.

14. The compound or pharmaceutically acceptable salt of claim 1 , wherein X 4 is a bond, —CH 2 —, or —N(R)—.

15. The compound or pharmaceutically acceptable salt of claim 1 , wherein X 5 is a bond.

16. The compound or pharmaceutically acceptable salt of claim 1 , wherein X 1 is —(O—CH 2 —CH 2 —CH 2 ) m —, m is 1, and X 2 is —C(O)—N(R)—.

17. The compound or pharmaceutically acceptable salt of claim 1 , wherein X 1 is —CH 2 —, —C(O)—,

18. The compound or pharmaceutically acceptable salt of claim 1 , wherein X 2 is a bond, —C(O)—, —C 1-5 alkyl-,

19. The compound or pharmaceutically acceptable salt of claim 1 , wherein X 3 is bond, —C 1-4 alkyl-, 4-6 membered cycloalkyl, or —N(R)—.

20. The compound or pharmaceutically acceptable salt of claim 1 , wherein X 3 is a bond, —C 1-4 alkyl-, —NH—,

or —C≡C—.

21. The compound or pharmaceutically acceptable salt of claim 1 , wherein X 4 is a bond,

—C 1-4 alkyl-, —CH 2 —CH 2 —N(R)—, or —N(R)—.

22. The compound or pharmaceutically acceptable salt of claim 1 , wherein X 5 is a bond, —C 1-4 alkyl-, —N(R)—, or —C(O)—N(R)—.

23. The compound or pharmaceutically acceptable salt of claim 1 , wherein L is

24. The compound or pharmaceutically acceptable salt of claim 1 , wherein Y is

25. The compound or pharmaceutically acceptable salt of claim 1 , wherein W is N.

26. The compound or pharmaceutically acceptable salt of claim 1 , wherein D is a bond.

27. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound of Formula (A) is a compound of Formula (B)

or a pharmaceutically acceptable salt thereof, wherein

W is CH or N;

D is a bond or —NH—;

Ring B1 is a 4-6 membered, fully saturated, partially unsaturated, or fully unsaturated monocyclic heterocycle or a 8-10 membered, fully saturated, spiro bicyclic heterocycle, wherein ring B1 has 1-3 heteroatoms independently selected from N, O, or S, and is optionally substituted with 1-3 groups selected from halo, —CH 3 , —CF 3 , —C(O)OH, —CH 2 OH, or a 5 membered heterocycloalkyl optionally substituted with oxo and having 1-2 heteroatoms independently selected from N or 0;

L is —X 1 —X 2 —X 3 —;

X 1 is —C(O)—N(R)—, —N(R)—C(O)—, —(O—CH 2 —CH 2 ) m —, —O(C 6 H 4 )—, —(O—CH 2 —CH 2 —CH 2 ) m —, —C 1-5 alkyl-, 7-12 membered spiro or fused bicyclic heterocycloalkyl having 1-3 heteroatoms independently selected from N, O, or S, or 4-6 membered monocyclic heterocycloalkyl having 1-2 heteroatoms independently selected from N, O, or S, wherein each of the monocyclic and bicyclic heterocycloalkyl of X 1 is optionally substituted with —CH 3 ;

X 3 is a bond, —C 1-4 alkyl-, —C≡C—, 4-6 membered cycloalkyl, —N(R)—, —(O—CH 2 —CH 2 ) p —, —(CH 2 —CH 2 —O) p —, 4-6 membered heterocycloalkyl having 1-2 heteroatoms independently selected from N, O, or S wherein the heterocycloalkyl is optionally substituted with —CH 3 ;

each R is independently —H or —C 1-3 alkyl;

each of m, n, and p is independently an integer from 1 to 3; and

Y is

28. The compound or pharmaceutically acceptable salt of claim 27 , wherein ring B1 is

and ring B1 is optionally substituted 1-3 groups selected from —CH 3 , —CH 2 OH, —C(O)OH, —CF 3 , —F,

29. The compound or pharmaceutically acceptable salt of claim 27 , wherein ring B1 is

30. The compound or pharmaceutically acceptable salt of claim 27 , wherein ring B1 is

31. The compound or pharmaceutically acceptable salt of claim 27 , wherein X 1 is

32. The compound or pharmaceutically acceptable salt of claim 27 , wherein X 2 is a bond, —C 1-5 alkyl-, 4-6 membered monocyclic cycloalkyl, or 4-6 membered monocyclic heterocycloalkyl having 1-2 heteroatoms independently selected from N, O, or S.

33. The compound or pharmaceutically acceptable salt of claim 27 , wherein X 2 is a bond, —C 1-3 alkyl-, —C(O)—,

34. The compound or pharmaceutically acceptable salt of claim 27 , wherein X 3 is a bond, —C 1-4 alkyl-, —N(R)—, —(O—CH 2 —CH 2 ) p —, —(CH 2 —CH 2 —O) p —, or a 4-6 membered heterocycloalkyl having 1-2 heteroatoms independently selected from N, O, or S wherein the heterocycloalkyl is optionally substituted with —CH 3 .

35. The compound or pharmaceutically acceptable salt of claim 27 , wherein X 3 is a bond,

36. The compound or pharmaceutically acceptable salt of claim 27 , wherein L is

37. The compound or pharmaceutically acceptable salt of claim 27 , wherein W is N and D is a bond.

38. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound of Formula (A) is a compound of Formula (C)

or a pharmaceutically acceptable salt thereof, wherein

W is CH or N;

Ring C is phenyl or a saturated, partially unsaturated, or fully unsaturated 5-6 membered monocyclic heterocycle having 1-2 heteroatoms independently selected from N, O, or S, wherein each of the phenyl and heterocycle of ring C is optionally substituted;

L is —X 1 —X 2 —X 3 —;

X 1 is —C(O)—N(R)—, —N(R)—C(O)—, —(O—CH 2 —CH 2 ) m —, —O—(C 6 H 4 )—, —(O—CH 2 —CH 2 —CH 2 ) m , —C 1-5 alkyl-, 7-12 membered spiro bicyclic heterocycloalkyl having 1-3 heteroatoms independently selected from N, O, or S, or 4-6 membered monocyclic heterocycloalkyl having 1-2 heteroatoms independently selected from N, O, or S, wherein each of the bicyclic heterocycloalkyl and the monocyclic heterocycloalkyl of X 1 is optionally substituted with —CH 3 ;

each R is independently —H or —C 1-3 alkyl; and

each of m, n, and p is independently an integer from 1 to 3.

39. The compound or pharmaceutically acceptable salt of claim 38 , wherein ring C is

40. The compound or pharmaceutically acceptable salt of claim 38 , wherein ring C is

41. The compound or pharmaceutically acceptable salt of claim 38 , wherein X 1 is a 4-6 membered monocyclic heterocycloalkyl having 1-2 heteroatoms independently selected from N, O, or S.

42. The compound or pharmaceutically acceptable salt of claim 38 , wherein X 1 is

43. The compound or pharmaceutically acceptable salt of claim 38 , wherein X 2 is a bond, —C 1-5 alkyl-, 4-6 membered monocyclic cycloalkyl, or 4-6 membered monocyclic heterocycloalkyl having 1-2 heteroatoms independently selected from N, O, or S.

44. The compound or pharmaceutically acceptable salt of claim 38 , wherein X 2 is a bond or —C 1-3 alkyl-.

45. The compound or pharmaceutically acceptable salt of claim 38 , wherein X 3 is a 4-6 membered cycloalkyl, —N(R)—, or a 4-6 membered heterocycloalkyl having 1-2 heteroatoms independently selected from N, O, or S wherein the heterocycloalkyl is optionally substituted with —CH 3 .

46. The compound or pharmaceutically acceptable salt of claim 38 , wherein X 3 is

47. The compound or pharmaceutically acceptable salt of claim 38 , wherein L is

48. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound of Formula (A) is a compound of Formula (D)

or a pharmaceutically acceptable salt thereof, wherein

W is CH or N;

Ring A is

L is —X 1 —X 2 —X 3 —;

X 1 is —C 1-5 alkyl- or 4-6 membered monocyclic heterocycloalkyl having 1-2 heteroatoms independently selected from N, O, or S wherein the monocyclic heterocycloalkyl of X 1 is optionally substituted with —CH 3 ;

X 2 is a bond, —C 1-5 alkyl-, or 4-6 membered monocyclic heterocycloalkyl having 1-2 heteroatoms independently selected from N, O, or S wherein the monocyclic heterocycloalkyl of X 1 is optionally substituted with —CH 3 ;

X 3 is a bond, —C 1-4 alkyl-, 4-6 membered monocyclic cycloalkyl, or 4-6 membered heterocycloalkyl having 1-2 heteroatoms independently selected from N, O, or S wherein the heterocycloalkyl is optionally substituted with —CH 3 ;

and

R 10 is halo, —C 1-5 alkyl, -3-6 membered cycloalkyl, 5-6 membered heterocycloalkyl, —CN, —OH, —CF 3 , —C(O)OH, —CH 2 OH, —CH 2 CH 2 OH,

49. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound of Formula (D) is a compound of Formula (D-1)

or a pharmaceutically acceptable salt thereof, wherein

W is CH or N;

Ring A is

L is —X 1 —X 2 —X 3 —;

50. The compound or pharmaceutically acceptable salt of claim 48 , wherein the compound of Formula (D) is a compound of Formula (D-2):

or a pharmaceutically acceptable salt thereof.

51. The compound or pharmaceutically acceptable salt of claim 48 , wherein ring A is or

52. The compound or pharmaceutically acceptable salt of claim 48 , wherein X 1 is a 4-6 membered monocyclic heterocycloalkyl having 1-2 heteroatoms independently selected from N, O, or S wherein the monocyclic heterocycloalkyl of X 1 is optionally substituted with —CH 3 .

53. The compound or pharmaceutically acceptable salt of claim 48 , wherein X 1 is

54. The compound or pharmaceutically acceptable salt of claim 48 , wherein X 2 is a bond, —C 1-5 alkyl-, 4-6 membered monocyclic cycloalkyl, or 4-6 membered monocyclic heterocycloalkyl having 1-2 heteroatoms independently selected from N, O, or S.

55. The compound or pharmaceutically acceptable salt of claim 48 , wherein X 2 is a bond or —C 1-4 alkyl-.

56. The compound or pharmaceutically acceptable salt of claim 48 , wherein X 3 is a bond, a 4-6 membered monocyclic cycloalkyl, or 4-6 membered monocyclic heterocycloalkyl having 1-2 heteroatoms independently selected from N, O, or S.

57. The compound or pharmaceutically acceptable salt of claim 48 , wherein X 3 is

58. The compound or pharmaceutically acceptable salt of claim 48 , wherein L is

59. The compound or pharmaceutically acceptable salt of claim 48 , wherein R 10 is

60. The compound or pharmaceutically acceptable salt of claim 48 , wherein R 10 is

61. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound of Formula (A) is a compound of Formula (E)

or a pharmaceutically acceptable salt thereof, wherein

D is a bond or —NH—;

W is N or CH;

Ring B is an optionally substituted 5-6 membered saturated, partially unsaturated, or fully unsaturated monocyclic heterocycle, or an optionally substituted 8-10 membered spiro bicyclic heterocycle, wherein ring B has 1-3 heteroatoms independently selected from N, O, or S;

L is —X 1 —X 2 —X 3 —X 4 —X 5 —;

X 1 is a bond, —C(O)—N(R)—, —N(R)—C(O)—, —(O—CH 2 —CH 2 ) m —, —O(C 6 H 4 )—, —(O—CH 2 —CH 2 —CH 2 ) m , —C 1-5 alkyl-, 7-12 membered spiro bicyclic heterocycloalkyl having 1-3 heteroatoms independently selected from N, O, or S, or 4-6 membered monocyclic heterocycloalkyl having 1-2 heteroatoms independently selected from N, O, or S, wherein each of the monocyclic and bicyclic heterocycloalkyl of X 1 is optionally substituted with —CH 3 ;

X 5 is a bond, —N(R)—, or —C(O)—N(R)—;

each R is independently —H or —C 1-3 alkyl;

each of m, n, and p is independently an integer from 1 to 3; and

wherein at least one of X 1 , X 2 , X 3 , X 4 , and X 5 has a nitrogen atom, and Y is directly bonded to L at a nitrogen atom of X 1 , X 2 , X 3 , X 4 , or X 5 .

62. The compound or pharmaceutically acceptable salt of claim 61 , wherein ring

wherein R 10 is

and wherein R 1 is a C 1-4 alkyl group.

63. The compound or pharmaceutically acceptable salt of claim 61 , wherein ring B is

wherein R 10 is

64. The compound or pharmaceutically acceptable salt of claim 61 , wherein ring B is

65. The compound or pharmaceutically acceptable salt of claim 61 , wherein R 10 is

66. The compound or pharmaceutically acceptable salt of claim 61 , wherein ring A is

67. The compound or pharmaceutically acceptable salt of claim 61 , wherein X 5 is —N(R)—.

68. The compound or pharmaceutically acceptable salt of claim 61 , wherein X 5 is —C(O)—N(R)—.

69. The compound or pharmaceutically acceptable salt of claim 61 , wherein X 5 is a bond.

70. The compound or pharmaceutically acceptable salt of claim 61 , wherein L is

71. The compound or pharmaceutically acceptable salt of claim 61 , wherein Y is

72. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound of Formula (A) is a compound of Formula (F)

or a pharmaceutically acceptable salt thereof, wherein

W is CH or N;

L is —X 1 —X 2 —X 3 —;

X 1 is —C(O)—N(R)—, —N(R)—C(O)—, —(O—CH 2 —CH 2 ) m —, —O(C 6 H 4 )—, —(O—CH 2 —CH 2 —CH 2 ) m , —C 1-5 alkyl-, 7-12 membered spiro bicyclic heterocycloalkyl having 1-3 heteroatoms independently selected from N, O, or S, or 4-6 membered monocyclic heterocycloalkyl having 1-2 heteroatoms independently selected from N, O, or S, wherein each of the monocyclic and bicyclic heterocycloalkyl of X 1 is optionally substituted with —CH 3 ;

X 2 is a bond, —C 1-5 alkyl-, —(O—CH 2 —CH 2 ) n —, —(CH 2 —CH 2 —O) n —, —N(R)—C(O)—, —N(R)—, —C(O)—, —C 1-5 alkyl-, 4-6 membered monocyclic cycloalkyl, or 4-6 membered monocyclic heterocycloalkyl having 1-2 heteroatoms independently selected from N, O, or S;

each R is independently —H or —C 1-3 alkyl;

each of m, n, and p is independently an integer from 1 to 3; and

Y is

73. The compound or pharmaceutically acceptable salt of claim 72 , wherein W is N.

74. The compound or pharmaceutically acceptable salt of claim 72 , wherein Y is

75. The compound or pharmaceutically acceptable salt of claim 72 , wherein X 1 is a 4-6 membered monocyclic heterocycloalkyl having 1-2 heteroatoms independently selected from N, O, or S, wherein each of the monocyclic heterocycloalkyl of X 1 is optionally substituted with —CH 3 .

76. The compound or pharmaceutically acceptable salt of claim 72 , wherein X 1 is

77. The compound or pharmaceutically acceptable salt of claim 72 , wherein X 1 is

78. The compound or pharmaceutically acceptable salt of claim 72 , wherein X 2 is a bond or —C 1-5 alkyl-.

79. The compound or pharmaceutically acceptable salt of claim 72 , wherein X 3 is a 4-6 membered monocyclic heterocycloalkyl having 1-2 heteroatoms independently selected from N, O, or S.

80. The compound or pharmaceutically acceptable salt of claim 72 , wherein X 3 is

81. The compound or pharmaceutically acceptable salt of claim 72 , wherein X 3 is or

82. The compound or pharmaceutically acceptable salt of claim 72 , wherein L is

83. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound of Formula (A) is a compound of Formula (G)

or a pharmaceutically acceptable salt thereof.

84. The compound or pharmaceutically acceptable salt of claim 83 , wherein R 1 is methyl.

85. The compound or pharmaceutically acceptable salt of claim 83 , wherein Y is

86. The compound or pharmaceutically acceptable salt of claim 83 , wherein W is N.

87. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound of Formula (A) is a compound of Formula (H)

or a pharmaceutically acceptable salt thereof.

88. The compound or pharmaceutically acceptable salt of claim 1 , wherein q is 0.

89. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound of Formula (A) is a compound of Formula (J)

or a pharmaceutically acceptable salt thereof.

90. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound of Formula (A) is a compound of Formula (K)

or a pharmaceutically acceptable salt thereof, wherein

Ring A is

wherein ring A is optionally and independently substituted with up to 3 substituents selected from halo, CN, carboxyl, NH 2 , and optionally substituted C 1-6 alkyl;

V is a bond or —CH 2 —; and

E and G are each independently a 5-6 membered heterocycloalkyl, wherein each heterocycloalkyl contains at least one nitrogen atom.

91. The compound or pharmaceutically acceptable salt of claim 90 , wherein D is a bond and W is a nitrogen atom.

92. The compound of pharmaceutically acceptable salt of claim 1 , wherein the compound of Formula (A) is a compound of Formula (M)

or a pharmaceutically acceptable salt thereof, wherein

R 10A is —H,

wherein

R 1 is C 1-4 alkyl;

X 1 is —C 1-5 alkyl-;

Ring C-1 is a 5-6 membered heterocycloalkyl having 1 nitrogen atom; and

Y is

93. The compound or pharmaceutically acceptable salt of claim 92 , wherein R 10A is —H or

94. The compound or pharmaceutically acceptable salt of claim 92 , wherein R 10A is

and R 1 is methyl, ethyl, propyl, iso-propyl, butyl, sec-butyl, or iso-butyl.

95. The compound or pharmaceutically acceptable salt of claim 92 , wherein R 1 is methyl.

96. The compound or pharmaceutically acceptable salt of claim 92 , wherein X 1 is methylene, ethylene, or propylene.

97. The compound or pharmaceutically acceptable salt of claim 92 , wherein X 1 is methylene.

98. The compound or pharmaceutically acceptable salt of claim 92 , wherein ring C-1 is

99. The compound or pharmaceutically acceptable salt of claim 92 , wherein ring C-1 is

100. A compound selected from Table 1, or a pharmaceutically acceptable salt thereof

TABLE 1

Compound

Number

Structure

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

101. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt of a compound of claim 1 and a pharmaceutically acceptable carrier, vehicle, or adjuvant.

102. A method of treating a disease or disorder mediated by degrading Bruton's tyrosine kinase, comprising administering to a patient or biological sample a compound or pharmaceutically acceptable salt of a compound of claim 1 .

103. The method of claim 102 , wherein the disease or disorder is cancer.

104. The method of claim 103 , wherein the cancer is a hematological cancer selected from myeloid leukemia (acute and chronic), acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome, Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma) hairy cell, mantle cell lymphoma, Waldenström's macroglobulinemia, marginal zone lymphoma, and follicular lymphoma.

105. The method of claim 102 , wherein the disease or disorder is an autoimmune disease.

106. The method of claim 105 , wherein the autoimmune disease is selected from uticaria, graft-versus-host disease, pemphigus vulgaris, achalasia, Addison's disease, Adult Still's disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti-GBM/anti-TBM nephritis, antiphospholipid syndrome, autoimmune angioedema, autoimmune dysautonomia, autoimmune encephalomyelitis, autoimmune hepatitis, autoimmune inner ear disease (AIED), autoimmune myocarditis, autoimmune oophoritis, autoimmune orchitis, autoimmune pancreatitis, autoimmune retinopathy, axonal and neuronal neuropathy (AMAN), Baló disease, Behcet's disease, benign mucosal pemphigoid, bullous pemphigoid, Castleman disease (CD), Celiac disease, Chagas disease, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic recurrent multifocal osteomyelitis (CRMO), Churg-Strauss Syndrome (CSS) or Eosinophilic Granulomatosis (EGPA), cicatricial pemphigoid, Cogan's syndrome, cold agglutinin disease, congenital heart block, coxsackie myocarditis, CREST syndrome, Crohn's disease, dermatitis herpetiformis, dermatomyositis, Devic's disease (neuromyelitis optica), discoid lupus, Dressler's syndrome, endometriosis, eosinophilic esophagitis (EoE), eosinophilic fasciitis, erythema nodosum, essential mixed cryoglobulinemia, evans syndrome, fibromyalgia, fibrosing alveolitis, giant cell arteritis (temporal arteritis), giant cell myocarditis, glomerulonephritis, goodpasture's syndrome, granulomatosis with polyangiitis, Graves' disease, Guillain-Barre syndrome, Hashimoto's thyroiditis, hemolytic anemia, Henoch-Schonlein purpura (HSP), herpes gestationis or pemphigoid gestationis (PG), hidradenitis suppurativa (HS) (Acne Inversa), hypogammalglobulinemia, IgA nephropathy, IgG4-related sclerosing disease, immune thrombocytopenic purpura (ITP), inclusion body myositis (IBM), interstitial cystitis (IC), juvenile arthritis, juvenile diabetes (Type 1 diabetes), juvenile myositis (JM), Kawasaki disease, Lambert-Eaton syndrome, leukocytoclastic vasculitis, lichen planus, lichen sclerosus, ligneous conjunctivitis, linear IgA disease (LAD), lupus, lyme disease chronic, Meniere's disease, microscopic polyangiitis (MPA), mixed connective tissue disease (MCTD), Mooren's ulcer, Mucha-Habermann disease, Multifocal Motor Neuropathy (MMN) or MMNCB, multiple sclerosis, myasthenia gravis, myositis, narcolepsy, neonatal lupus, neuromyelitis optica, neutropenia, ocular cicatricial pemphigoid, optic neuritis, palindromic rheumatism (PR), PANDAS, paraneoplastic cerebellar degeneration (PCD), paroxysmal nocturnal hemoglobinuria (PNH), Parry Romberg syndrome, pars planitis (peripheral uveitis), Parsonnage-Turner syndrome, pemphigus, peripheral neuropathy, perivenous encephalomyelitis, pernicious anemia (PA), POEMS syndrome, polyarteritis nodosa, polyglandular syndromes type I, II, III, polymyalgia rheumatica, polymyositis, postmyocardial infarction syndrome, postpericardiotomy syndrome, primary biliary cirrhosis, primary sclerosing cholangitis, progesterone dermatitis, psoriasis, psoriatic arthritis, pure red cell aplasia (PRCA), pyoderma gangrenosum, Raynaud's phenomenon, reactive Arthritis, reflex sympathetic dystrophy, relapsing polychondritis, restless legs syndrome (RLS), retroperitoneal fibrosis, rheumatic fever, rheumatoid arthritis, sarcoidosis, Schmidt syndrome, scleritis, scleroderma, Sjögren's syndrome, sperm and testicular autoimmunity, stiff person syndrome (SPS), subacute bacterial endocarditis (SBE), Susac's syndrome, sympathetic ophthalmia (SO), Takayasu's arteritis, temporal arteritis (giant cell arteritis), thrombocytopenic purpura (TTP), Tolosa-Hunt syndrome (THS), transverse myelitis, Type 1 diabetes, ulcerative colitis (UC), undifferentiated connective tissue disease (UCTD), uveitis, vasculitis, vitiligo, Vogt-Koyanagi-Harada Disease, and Wegener's granulomatosis (or Granulomatosis with Polyangiitis (GPA)).

Assignments (1)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2020

From: ROBBINS, DANIEL W.; SANDS, ARTHUR T.; MCINTOSH, JOEL; MIHALIC, JEFFREY; WU, JEFFREY; KATO, DAISUKE; WEISS, DAHLIA; PENG, GE

To: NURIX THERAPEUTICS, INC.

Reel/Frame 054536/0826 →

Continuity (5)

Provisional Application 62901984 · Sep 18, 2019

Provisional Application 62887812 · Aug 16, 2019

Provisional Application 62836398 · Apr 19, 2019

Provisional Application 62767819 · Nov 15, 2018

Provisional Application 62745786 · Oct 15, 2018

Cited By (4)

US 12,377,106 US 12,582,722 US 12,583,862 US 12,600,732